Ligand Pharmaceuticals (LGND) Depreciation & Amortization (CF) (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $8.2 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 6.32% year-over-year to $8.2 million; the trailing twelve-month figure through Mar 2026 stood at $33.2 million (down 5.74% YoY), and the FY2025 full-year result was $33.8 million, down 4.15% from the prior year.
• Depreciation & Amortization (CF) held at $8.2 million in Q1 2026, from $8.2 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $13.7 million in Q1 2022 to a low of $8.2 million in Q4 2025.
• A 5-year average of $9.7 million and a median of $8.9 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) gained 8.67% in 2022 and slumped 36.11% in 2023, its largest moves.
• Tracing LGND's Depreciation & Amortization (CF) over 5 years: stood at $11.1 million in 2022, then fell by 19.93% to $8.9 million in 2023, then declined by 3.24% to $8.6 million in 2024, then retreated by 4.79% to $8.2 million in 2025, then rose by 0.02% to $8.2 million in 2026.
• Business Quant data shows LGND's Depreciation & Amortization (CF) at $8.2 million in Q1 2026, $8.2 million in Q4 2025, and $8.3 million in Q3 2025.